The care of pediatric, adolescent and young adult patients with hematologic malignancies and myelodysplastic and myeloproliferative disorders continues to evolve, raising new opportunities and challenges in the diagnosis, classification and treatment of these conditions. This session will focus on advances in the management of a spectrum of these disorders with an emphasis on new therapeutic opportunities emerging from recent laboratory discoveries.
Dr. Elizabeth Raetz will summarize recent advances in the treatment and outcomes for pediatric patients with T cell acute lymphoblastic leukemia (T-ALL). Recent discoveries in the biology of T-ALL and their potential to impact therapy in the future will also be discussed.
Dr. John Sandlund will review age related differences in lymphoma biology and treatment outcomes for children, adolescents and young adults (AYA) with non-Hodgkin lymphoma. Recommendations for the AYA population and opportunities for new research initiatives will be presented.
Dr. Henrik Hasle will discuss challenges in making a diagnosis in the rare pediatric myelodysplastic syndromes (MDS) and juvenile myelomonocytic leukemia (JMML). The therapeutic aim and strategies of pediatric MDS are very different from adult MDS. Recent genetic insights in JMML that may be used for treatment stratification will be reviewed.